CareDx says final Medicare LCD maintains coverage for transplant rejection surveillance tests

• CareDx clarified that Medicare finalized a Local Coverage Determination supporting molecular surveillance testing for solid organ transplant rejection.
• Policy maintains coverage across kidney, heart, lung offerings, setting surveillance test frequency limits for years 1-3 post-transplant; for-cause testing unchanged.
• Final LCD published July 16, 2026; effective Aug. 30, 2026, reducing reimbursement uncertainty for key transplant testing products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260716462755) on July 16, 2026, and is solely responsible for the information contained therein.